Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Design Therapeutics ( (DSGN) ) is now available.
On September 9, 2025, Arsani William, M.D., resigned from the board of directors of Design Therapeutics, Inc., with no disagreements related to the company’s operations. On the same day, Justin Gover was appointed as a Class III director and chair of the Compensation Committee, with his term ending at the 2027 annual meeting of stockholders. Mr. Gover will receive an annual cash retainer and stock options as part of the company’s compensation policy.
The most recent analyst rating on (DSGN) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Design Therapeutics stock, see the DSGN Stock Forecast page.
Spark’s Take on DSGN Stock
According to Spark, TipRanks’ AI Analyst, DSGN is a Neutral.
Design Therapeutics has significant financial challenges due to its lack of revenue and profitability, which heavily weighs on its score. Despite a strong balance sheet and positive technical indicators suggesting short-term momentum, the negative valuation metrics and absence of earnings diminish its overall appeal. The stock is risky and reliant on future revenue growth for improvement.
To see Spark’s full report on DSGN stock, click here.
More about Design Therapeutics
Average Trading Volume: 123,408
Technical Sentiment Signal: Buy
Current Market Cap: $331.4M
See more data about DSGN stock on TipRanks’ Stock Analysis page.